These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31783119)

  • 1. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
    Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
    Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
    Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
    Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
    Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
    PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
    Chen ZS; Huang X; Talbot K; Chan HYE
    Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
    Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
    Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
    Li YX; Sibon OCM; Dijkers PF
    J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context.
    Jazurek-Ciesiolka M; Ciesiolka A; Komur AA; Urbanek-Trzeciak MO; Krzyzosiak WJ; Fiszer A
    J Mol Biol; 2020 Dec; 432(24):166699. PubMed ID: 33157084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
    Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV
    J Neurol Sci; 2023 Nov; 454():120828. PubMed ID: 37865002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
    Krauss S; Nalavade R; Weber S; Carter K; Evert BO
    Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.
    Prudencio M; Garcia-Moreno H; Jansen-West KR; Al-Shaikh RH; Gendron TF; Heckman MG; Spiegel MR; Carlomagno Y; Daughrity LM; Song Y; Dunmore JA; Byron N; Oskarsson B; Nicholson KA; Staff NP; Gorcenco S; Puschmann A; Lemos J; Januário C; LeDoux MS; Friedman JH; Polke J; Labrum R; Shakkottai V; McLoughlin HS; Paulson HL; Konno T; Onodera O; Ikeuchi T; Tada M; Kakita A; Fryer JD; Karremo C; Gomes I; Caviness JN; Pittelkow MR; Aasly J; Pfeiffer RF; Veerappan V; Eggenberger ER; Freeman WD; Huang JF; Uitti RJ; Wierenga KJ; Marin Collazo IV; Tipton PW; van Gerpen JA; van Blitterswijk M; Bu G; Wszolek ZK; Giunti P; Petrucelli L
    Sci Transl Med; 2020 Oct; 12(566):. PubMed ID: 33087504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward understanding Machado-Joseph disease.
    Costa Mdo C; Paulson HL
    Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis.
    Chakraborty A; Tapryal N; Venkova T; Mitra J; Vasquez V; Sarker AH; Duarte-Silva S; Huai W; Ashizawa T; Ghosh G; Maciel P; Sarkar PS; Hegde ML; Chen X; Hazra TK
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8154-8165. PubMed ID: 32205441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
    Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
    Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preimplantation Genetic Testing of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease-Robust Tools for Direct and Indirect Detection of the
    Lian M; Tan VJ; Taguchi R; Zhao M; Phang GP; Tan AS; Liu S; Lee CG; Chong SS
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
    Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
    J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
    Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
    Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease.
    Raposo M; Hübener-Schmid J; Tagett R; Ferreira AF; Vieira Melo AR; Vasconcelos J; Pires P; Kay T; Garcia-Moreno H; Giunti P; Santana MM; Pereira de Almeida L; Infante J; van de Warrenburg BP; de Vries JJ; Faber J; Klockgether T; Casadei N; Admard J; Schöls L; Riess O; ; Costa MDC; Lima M
    Neurobiol Dis; 2024 Apr; 193():106456. PubMed ID: 38423193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FipoQ/FBXO33, a Cullin-1-based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein.
    Chen ZS; Wong AKY; Cheng TC; Koon AC; Chan HYE
    J Neurochem; 2019 Jun; 149(6):781-798. PubMed ID: 30685895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATXN3: a multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3.
    Hernández-Carralero E; Quinet G; Freire R
    Expert Rev Mol Med; 2024 Sep; 26():e19. PubMed ID: 39320846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.